Global Acute Lung Injury Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Acute Lung Injury market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Acute Lung Injury market."
Acute lung injury is a life-threatening condition caused by severe acute hypoxemic respiratory failure. It is a key source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema.
This kind of injury has a substantial impact on public health, with a high incidence across the world and it requires administration of a fast and goal-oriented therapy to suppress further lung damage.
Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. 

The global Acute Lung Injury market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Acute Lung Injury volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Lung Injury market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Altor BioScience
    FirstString Research
    GlaxoSmithKline
    Forschung und Entwicklung
    Commence Bio
    CompleGen
    Histocell S.L.
    Stemedica Cell Technologies
    Windtree Therapeutics
    S-Evans Biosciences

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Pharmacotherapy
    Mechanical Ventilation
    Adjunctive Procedures
    Fluid Management
    Others

Segment by Application
    Hospitals
    Clinics
    Others